Please ensure Javascript is enabled for purposes of website accessibility

Merck's Keytruda Receives Priority Review for a Key Indication

By Cory Renauer – Apr 7, 2020 at 11:11AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An approval would give the immunotherapy another big leg up on Bristol Myers Squibb's similar treatment Opdivo.

Merck's (MRK 0.18%) application for permission to treat a large cohort of advanced-stage cancer patients with Keytruda has been accepted for a priority review by the FDA. The company is seeking approval for the drug to be used as a treatment for anyone with solid tumors that harbor more genetic mutations than usual.

Keytruda from Merck and Opdivo from Bristol Myers Squibb (BMY -0.77%) use the same mechanism to make it harder for tumors to hide from the immune system. In January 2019, Bristol Myers Squibb withdrew an FDA application to use Opdivo plus Yervoy as a treatment for newly diagnosed lung cancer patients with a high tumor mutational burden (TMB). It withdrew the application because long-term outcome data didn't suggest a strong survival benefit for the combination compared to standard chemotherapy in the first-line lung cancer setting.

Healthcare provider caring for a hospital patient.

Image source: Getty Images.

Merck, however, is attempting to earn approval for its PD-1 inhibitor as a second-line treatment for solid tumors regardless of their origination site based on response rate data from its single-arm Keynote-158 study. Keytruda shrank tumors for 34.3% of 233 patients with tumors deficient in DNA mismatch repair, a condition that coincides with a high tumor mutational burden 97% of the time.

Straight to the top

In 2019, sales of Keytruda soared 88% to $7.2 billion, and there's still more room for them to grow. Previous approvals for it to be used to treat lung cancer are expected to make Keytruda the world's top-selling drug in a few short years.  

In 2017, the FDA approved Keytruda as a second-line treatment for patients with mismatch repair-deficient tumors based on results from five different studies, including Keynote-158. If it's approved to treat the larger population of patients with high TMB, sales of Merck's blockbuster immunotherapy could get another big boost. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$87.60 (0.18%) $0.16
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$69.70 (-0.77%) $0.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.